Rare cardiovascular diseases affect 5% of the world’s population. Rare disease training for clinicians is essential to suspect and diagnose underlying rare diseases and to work effectively with ...

A phase 2 trial shows combining intravesical recombinant BCG with chemoimmunotherapy in MIBC yields a higher than expected pathologic complete response rate. Intravesical recombinant bacillus Calmette ...